Xenon’s Add-On Epilepsy Treatment Shows Promising Phase IIb Efficacy, Safety

Results from the Phase IIb X-TOLE study showed that Xenon Pharmaceuticals’ investigational potassium channel opener XEN1101 could safely reduce seizure burden in adults with focal epilepsy, the company announced Monday.